Project Grant HT94252510032
Award Date
12/15/24
Completion Date
12/14/27
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Evanston, IL 60208, USA
Similar Awards
This $640,000 federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) supports research by Northwestern University to enhance bispecific antibody therapy with nanoparticle-based photothermal therapy. The project aims to develop innovative approaches to transform healthcare for military service members and the broader public. The research will be conducted at Northwestern University's Sponsored...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,301,250.00 to Health Research, Inc. at its Roswell Park Division in Buffalo, NY to conduct research on "Inhibiting MDSC Biogenesis to Augment Immunotherapy Efficacy in Triple-Negative Breast Cancer". The 3-year award, which began on March 1, 2025 and runs through February 29, 2028, supports advanced biomedical research...
This federal Project Grant award, valued at $705,263, was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The funding supports a 3-year research project at Northwestern University to conduct single-cell tracking of the transformation of lung adenocarcinoma to small cell lung cancer. The project aims to generate novel scientific insights and develop innovative approaches to understanding and managing this complex...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $1,612,104.00 to the University of Chicago to develop and evaluate "senescent tumor cell-loaded dendritic cell vaccines for breast cancer." The award, which runs from February 1, 2025 through January 31, 2028, supports advanced medical research to transform healthcare for military service members and the broader public....
This $2,542,500.00 federal Project Grant award was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support research on therapeutic targeting of the tumor microenvironment in triple-negative breast cancer patients at high risk of relapse and preclinical models of lung metastases. The grant was awarded to Weill Medical College of Cornell University, a prominent academic medical institution, with a performance period from May 15, 2025...
The U.S. Department of Defense, through the Military Medical Research and Development (CFDA 12.420) federal grant program, awarded a $505,071 Project Grant to The University of Texas MD Anderson Cancer Center. The grant, awarded on February 15, 2025, supports the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" research project. The funding will enable the cancer center to conduct advanced biomedical research focused on...
This $1,535,039 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development Program (CFDA 12.420) supports research conducted by Wake Forest University Health Sciences (WFUHS) to study how the breast tissue microbiota regulates immune checkpoint blockade therapy responsiveness in triple-negative breast cancer. The research aims to advance scientific understanding and develop new treatment approaches for this aggressive form of breast cancer that...
The federal Project Grant award provides $1,151,250.00 to Texas A&M University System Health Science Center to develop a unique small molecule for triple-negative breast cancer. The grant is funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research initiatives to improve health outcomes for military service members, veterans, and the public. The award period runs from July 1, 2024 to June 30, 2027....
This $871,016 Project Grant awarded on January 1, 2024 by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the Beckman Research Institute of the City of Hope supports research on a highly tumor-specific oncolytic virus combined with a viral protein-target T cell engager for the treatment of triple-negative breast cancer. The grant aims to develop innovative therapies for this aggressive form of breast cancer that impacts military personnel and veterans. As a...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $661,072 to Northwestern University to develop a first-in-class small molecule inhibitor targeting the USP22 oncoprotein for the treatment of triple negative breast cancer. The goal is to create a novel therapy with both immunotherapeutic and anti-cancer stem cell properties. The project involves a collaborative effort with the startup company Exomira Medicine Inc., which will receive a...